key: cord-1011809-pbhvq1nh
authors: Coleman, Kristen K; Tay, Douglas Jie Wen; Sen Tan, Kai; Ong, Sean Wei Xiang; Son, Than The; Koh, Ming Hui; Chin, Yi Qing; Nasir, Haziq; Mak, Tze Minn; Chu, Justin Jang Hann; Milton, Donald K; Chow, Vincent T K; Tambyah, Paul Anantharajah; Chen, Mark; Wai, Tham Kwok
title: Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted by COVID-19 Patients while Breathing, Talking, and Singing
date: 2021-08-06
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab691
sha: cc1cbcfcf81fb99a424d0e810438f01e2e14c2fd
doc_id: 1011809
cord_uid: pbhvq1nh

BACKGROUND: Multiple SARS-CoV-2 superspreading events suggest that aerosols play an important role in driving the COVID-19 pandemic. To better understand how airborne SARS-CoV-2 transmission occurs, we sought to determine viral loads within coarse (>5μm) and fine (≤5μm) respiratory aerosols produced when breathing, talking, and singing. METHODS: Using a G-II exhaled breath collector, we measured viral RNA in coarse and fine respiratory aerosols emitted by COVID-19 patients during 30 minutes of breathing, 15 minutes of talking, and 15 minutes of singing. RESULTS: Thirteen participants (59%) emitted detectable levels of SARS-CoV-2 RNA in respiratory aerosols, including 3 asymptomatic and 1 presymptomatic patient. Viral loads ranged from 63–5,821 N gene copies per expiratory activity per participant, with high person-to-person variation. Patients earlier in illness were more likely to emit detectable RNA. Two participants, sampled on day 3 of illness, accounted for 52% of the total viral load. Overall, 94% of SARS-CoV-2 RNA copies were emitted by talking and singing. Interestingly, 7 participants emitted more virus from talking than singing. Overall, fine aerosols constituted 85% of the viral load detected in our study. Virus cultures were negative. CONCLUSIONS: Fine aerosols produced by talking and singing contain more SARS-CoV-2 copies than coarse aerosols and may play a significant role in SARS-CoV-2 transmission. Exposure to fine aerosols, especially indoors, should be mitigated. Isolating viable SARS-CoV-2 from respiratory aerosol samples remains challenging, and whether this can be more easily accomplished for emerging SARS-CoV-2 variants is an urgent enquiry necessitating larger-scale studies.

Coronavirus disease 2019 is caused by the highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Irrespective of symptomatology, COVID-19 patients can harbor high viral loads of SARS-CoV-2 in their respiratory tracts [1, 2] , and emit SARS-CoV-2 RNA into the air [3, 4] , which may be culturable under favorable circumstances and collection methods [5] .

Although virus emissions from talking and singing have not been measured, these expiratory activities are hypothesized to play a crucial role in virus transmission [6] . A significant proportion of SARS-CoV-2 transmission is estimated to be from asymptomatic individuals [7] , and multiple SARS-CoV-2 superspreading events [8] [9] [10] suggest that aerosols may be critical in driving the COVID-19

pandemic. Thus, refined public health measures are likely needed to contain the virus, especially in under-vaccinated populations.

Respiratory aerosols range from 0.1-100μm in diameter and can be categorized as coarse (>5μm) and fine (≤5μm) aerosols, based on where they deposit in the respiratory tract [11] . Coarse aerosols are inhalable and deposit in the upper airways, whereas fine aerosols are respirable and deposit in the lower airways. The amount of infectious virus these size fractions carry and their relative importance to SARS-CoV-2 transmission and infection is not well-understood. Experimental studies of non-human primates have demonstrated that COVID-19 may be anisotropic [12] as more severe illness results from inhaling infectious aerosols that are 1-3μm in diameter when compared to direct intranasal and intratracheal inoculation [13] . Other models, however, demonstrate a disease spectrum similar to humans with combined intranasal and intratracheal inoculation [14] . Cynomolgus macaques also shed more SARS-CoV-2 in fine aerosols when compared to coarse aerosols [15] . To better understand how SARS-CoV-2 spreads, and to help refine public health measures in mitigating SARS-CoV-2 transmission, we sought to measure viral loads in coarse and fine respiratory aerosols emitted by COVID-19 patients during breathing, talking, and singing.

A c c e p t e d M a n u s c r i p t

Participants were recruited from February-April 2021 at the National Centre for Infectious Diseases in Singapore. During this outbreak phase, as per national public health policy, all persons in Singapore with confirmed SARS-CoV-2 infection, regardless of symptom or clinical status, were admitted for inpatient isolation and evaluation before transfer to designated isolation facilities. All newly admitted patients were screened based on the following inclusion criteria: age ≥21 years and positive for COVID-19 via reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

Basic demographic data were recorded. Symptom data were collected based on a list of seven prespecified symptoms. For asymptomatic individuals, the day of diagnosis was recorded as day one of illness. Cycle threshold (Ct) values of clinical respiratory samples and SARS-CoV-2 serology test results were obtained from medical records. Virus genome sequence data were obtained from National Public Health Laboratory records.

Expiratory samples were collected using the G-II exhaled breath collector, described in detail by

McDevitt et al. [16] . Briefly, study participants were seated facing the truncated cone-shaped inlet, with air drawn continuously (130L/min) around the subject's head and into the sampler ( Figure 1 ).

The cone served as a capture type ventilation hood which allowed the collection of expiratory particles with minimal fugitive emissions. Participants were asked to perform three separate expiratory activities on the same day: 30 minutes of tidal breathing, 15 minutes of talking, and 15 minutes of singing. For the talking activity, participants were asked to repeat passages read to them from the children's book, -Green Eggs and Ham‖ by Dr. Seuss. For the singing activity, participants were asked to sing -Happy Birthday‖, -ABC song‖, -Twinkle, Twinkle, Little Star‖, and -We Wish You a Merry Christmas‖ with background music. Aerosols were collected in two size fractions, namely coarse (>5μm) and fine (≤5μm). The coarse fraction was collected by impaction on a Teflon® surface. The Teflon® impactor was swabbed thrice, end-to-end, with a flocked swab first dipped in M a n u s c r i p t 1× phosphate buffered saline (PBS) solution with 0.1% bovine serum albumin (BSA). The swab was rotated during swabbing to ensure that all surfaces of the flocked tip were in contact with the impactor for optimal retrieval of coarse particles. The flocked swab was then placed in a 15mL conical tube containing 1mL of 1× PBS with 0.1% BSA. Fine particles were collected by condensation growth and impaction on a steel surface into a reservoir of 1× PBS with 0.1% BSA and collected into 50mL conical tubes. Condensation growth was achieved by injecting a small amount of steam into the already humid inlet air and breath and immediately cooling the airstream in a heat exchanger held at -2˚C to achieve supersaturation conditions sufficient to grow fine particles ≥0.05µm in diameter to ≥1.0µm. In between each activity, the G-II was decontaminated with 10% bleach, rinsed with water, and wiped dry.

Samples were transported to and processed in the National University of Singapore Biosafety Level 3

Laboratory on the same day as collection. See Supplementary Materials for detailed laboratory methods. Coarse fraction swab samples were vortexed and aliquoted into 1.5mL screw-capped tubes.

Fine fraction samples were concentrated with centrifugal ultrafiltration and topped up to 1.6mL with media. Vero E6 cells were used to culture fine fraction samples on the same day of processing. Coarse fraction samples were not cultured as the impaction method was not designed for culture analysis [16] . RNA was extracted from each expiratory sample using the QIAamp MinElute Virus Spin Kit (Qiagen, Germany) according to the manufacturer's instructions. The CDC N1 assay (Centers for Disease Control and Prevention, USA) was performed for the detection of SARS-CoV-2. All samples were analyzed in duplicates. Viral RNA copies were calculated from a standard curve constructed with the N gene positive control plasmid (Integrated DNA Technologies, USA).

Data analyses were completed using STATA version 13.0 (StataCorp, College Station, Texas, USA).

Fisher's exact test was used to compare categorical variables, while Mann-Whitney U test was used to compare continuous variables between patients with and without detectable virus to identify variables A c c e p t e d M a n u s c r i p t associated with viral shedding in respiratory aerosols. Kruskal-Wallis test was used to compare median viral loads of different respiratory activities within the subgroup of patients with detectable virus in respiratory aerosols. All statistical tests were two-sided and a p-value of <0.05 was considered significant.

Twenty-three patients were enrolled in the study, including 1 patient who withdrew before sample collection. Among the 22 remaining participants, 19 (86%) were male, with median age of 38 years (range 23-66). Five (23%) were asymptomatic (never developed symptoms). Thirteen (59%) emitted detectable levels of SARS-CoV-2 RNA in respiratory aerosols (Table 1) (Table 2 ). However, the median day of illness was significantly different: patients with detectable viral RNA in aerosols were earlier in the course of illness (median day of illness of 3 versus 5, p-value=0.025). The highest emitters (Participants 12 and 16) were sampled on day 3 of illness and accounted for 52.4% of the total viral load captured in our study.

Six participants (27%) emitted detectable levels of SARS-CoV-2 RNA from all the expiratory activities. Two (9%) emitted detectable levels only from fine speech aerosols. Another two emitted detectable levels only from singing. No patients were observed to have sneezed during sample collection; however, two participants were observed to be coughing. Participant 4, who emitted 417 RNA copies in fine speech aerosols, was coughing during talking and singing. Participant 22 coughed frequently during all three activities but did not emit detectable viral RNA. Altogether, most SARS-CoV-2 RNA copies were emitted by singing (53%), followed by talking (41%) and breathing (6%) A c c e p t e d M a n u s c r i p t (Table 3) . Viral loads in respiratory aerosols differed significantly between the three activities, with 7 participants emitting more virus from talking than singing. Comparing patients with detectable SARS-CoV-2 RNA in aerosols (n=13), the median number of viral N gene copies generated during singing was 713.6 (IQR 135.1-1216.1), compared to 477.9 (IQR 234.5-1356.6) for talking, and 63.5 (0-227.6) for breathing (Kruskal-Wallis test, p=0.026). Further comparison revealed that this difference remained significant for fine aerosols, but not for coarse aerosols (Table 4 ). Altogether, fine aerosols (≤5µm in diameter) constituted 85.4% of the total viral RNA load detected in our study.

Sixteen participants (73%) were infected with a SARS-CoV-2 variant of concern (VOC) or variant of interest (VOI) during our study (Table 1) . Due to the small number of non-VOC/VOI variants, aerosol shedding patterns related to variant type could not be determined.

Virus cultures were negative after two consecutive passages. Vero E6 cells infected with a known SARS-CoV-2 isolate (positive control) displayed distinct CPE, whereas uninfected Vero E6 cells (negative control) remained as a healthy cell monolayer.

Our study demonstrates that SARS-CoV-2 can be aerosolized in the absence of coughing, sneezing, and aerosol-generating medical procedures. More than half of our study participants emitted detectable levels of SARS-CoV-2 RNA in respiratory aerosols, including 3 asymptomatic patients and 1 presymptomatic patient. Patients earlier in illness were more likely to emit detectable levels of virus, which is congruent with studies demonstrating higher viral loads in clinical samples in early illness [17] . Two participants sampled on day 3 of illness accounted for 52.4% of the total viral load captured A c c e p t e d M a n u s c r i p t in our study, which aligns with studies on overdispersion [18] , and the predominance of superspreading events in transmission dynamics. Although the overall viral RNA loads were relatively low, they differed significantly between breathing, talking, and singing, with singing generating the most virus in aerosols, and breathing the least. However, 7 participants emitted similar or more RNA copy numbers from talking when compared to singing. Although voice amplitude was not measured in our study, SARS-CoV-2 aerosol shedding models demonstrate similar aerosol emission rates for talking loudly and singing [18] . Overall, 85% of the total viral load was emitted in fine aerosols (≤5µm in diameter) when compared to coarse aerosols (>5µm in diameter), which is consistent with the observation that smaller particles (0.65-4.7µm) account for 77-79% of total virus particles shed by experimentally infected cynomolgus macaques [15] . Our results demonstrate the potential for fine respiratory aerosols to play an important role in community transmission of SARS-CoV-2, which is in agreement with other expert views suggesting that SARS-CoV-2 transmission events are driven by the airborne route [19] , and could explain the difficulty in containing the virus.

Our results support the calls for proper respiratory protection (i.e., universal masking and N95, FFP3 respirators or equivalent for healthcare and frontline workers), airflow patterns, ventilation, filtration, and safe airborne disinfection, particularly in indoor environments [20] such as schools, to reduce exposure to SARS-CoV-2 in fine aerosolsalbeit live virus could not be isolated.

While it has been previously shown that COVID-19 patients can emit infectious virus-laden aerosols into their environments [5, 21] , most environmental SARS-CoV-2 sampling studies have been unable to mechanically retrieve and isolate viable virus from ambient air in the vicinity of COVID-19 patients [22] . Hence, the infectious proportion of virus emitted from patient expiration remains unclear. In our study, the inability to isolate viable virus from respiratory aerosol samples collected directly from patients (not from their environments) is likely related to the low viral load in our samples compared to those generally found in culturable clinical samples. Our study was limited in that respiratory swabs were not collected on the day of aerosol sampling for comparison of culturability. However, studies have reported that for clinical SARS-CoV-2 samples, viral loads of 10 5 to 10 6 genome copies/mL are required for isolation of SARS-CoV-2 in vitro [23] . Our sampling M a n u s c r i p t methodology yielded viral RNA loads below 10 3.8 genome copies per sample, suggesting that increased sampling duration is needed to reach culturable virus levels. However, critical mutations in certain SARS-CoV-2 variants can augment virus infectivity [24] , e.g., some patients infected with the Delta variant demonstrate higher viral loads in their respiratory swabs [25] . These SARS-CoV-2 variants, especially Delta [25] , can cause a higher secondary attack rate than older strains [26] and may be more successfully cultured from aerosol samples in future studies, especially if patients are sampled during the short window of enhanced viral shedding [27] . More studies are warranted to test this hypothesis given that only 4 study participants were infected with non-VOC/VOI variants, and only one with Delta. Thus, aerosol shedding patterns between early and new SARS-CoV-2 strains could not be compared. Additionally, for virus culture in our study, we did not employ Vero E6 cells expressing the transmembrane serine protease 2 (TMPRSS2) which can bind and cleave SARS-CoV-2 spike protein more efficiently and facilitate early surface-mediated cell entry and viral fusion [28, 29] . Although SARS-CoV-2 from saliva and respiratory swabs can be isolated using classical Vero E6 cells, a more sensitive culture assay using Vero E6 TMPRSS2 cells may be superior for culturing virus from patient aerosol samples. Human bronchial epithelial cells may also be more susceptible to infection with wildtype viruses than Vero cells [24] . Further efforts to identify optimal culture methods for exhaled breath and environmental samples are warranted.

We observed that patients earlier in illness were more likely to emit detectable levels of virus in aerosols, which is in line with a recent non-human primate model indicating that SARS-CoV-2 aerosol shedding is substantially reduced 4 days post-infection when compared to 2 days postinfection [15] , and concurs with the higher viral loads and greater infectivity observed in human clinical samples collected early in illness [17] . Additionally, neutralizing antibodies start to appear in COVID-19 patients five days post-symptom onset [30] , which may reduce and neutralize virus that is shed, preventing isolation in cell culture. Although 17 participants (77%) were seronegative at diagnosis (Table 1) , a serology test nearer the sampling day would have been a better indicator of infectiousness during aerosol sampling. Although 12 (55%) were sampled with the G-II machine within 5 days post-symptom onset (plus Participant 9, sampled 2 days pre-symptom onset), we failed A c c e p t e d M a n u s c r i p t to isolate viable virus, suggesting that participants might need to be sampled at an earlier stage of infection, or for longer durations. Furthermore, two participants sampled on day 3 of illness accounted for 52% of the total viral load captured in our study, which aligns with a recent model of SARS-CoV-2 aerosol shedding demonstrating broad heterogeneity among cases [18] . Recent data also suggest that only 2% of infected individuals carry 90% of the total viral load circulating in a population at any given time [27] . This implies that only 1 in 50 active cases at any given time would be expected to have high viral loads in exhaled breath. The likelihood of capturing such cases was limited by our small sample size. The small sample size of our cohort was also further limited by a skewed demographic toward younger males. Thus, researchers must work with contact tracers to proactively isolate and strategically sample large numbers of close contacts of individuals recently infected with SARS-CoV-2 to capture the most accurate data on viral shedding in the community across all demographic ranges, for which research gaps remain.

To our knowledge, this is the first study to quantify SARS-CoV-2 in aerosols generated by singing. Our results support existing laboratory simulation data [31, 32] , and can explain the many airborne SARS-CoV-2 outbreaks involving singing [8, 9, [33] [34] [35] . Higher concentrations of aerosols are generated by singing compared to talking, with loudness having a large effect on the number of aerosols produced [31, 32, 36] . However, there was high person-to-person variation in virus emission between expiratory activities in our study. Individuals who generate an above-average amount of aerosols (known as -super-emitters‖) also exist, but it is unclear what causes this phenomenon [37] .

Interestingly, a small number of individuals produce more aerosols from breathing when compared to talking [32] , which may partially explain the asymptomatic participant in our study who emitted more SARS-CoV-2 from breathing rather than talking. The physiological or experimental reasons underlying these observations are unclear.

Our results underscore the importance of reducing exposure to fine respiratory aerosols through non-pharmaceutical interventions (NPIs), such as universal masking, physical distancing, and A c c e p t e d M a n u s c r i p t

We thank Tan Chorh Chuan and Leo Yee-Sin for their administrative support, and Julian Tang for his virology insights. We also thank Chandra Sekhar and David Kok Wai Cheong for assembling the G-II machine, and Somayeh Youssefi, Jacob Bueno De Mesquita and Jovan Pantelic for guiding the G-II assembly and operation. We thank Raymond Lin and Lin Cui for sharing whole genome sequencing data. We also thank Margaret Soon, Phoon Long Yoke, Loh Kyun Yen, Pang Jia Xin, and all nursing, infection control, and operational staff at the National Centre for Infectious Diseases for their support.

Lastly, we thank the NUS BSL-3 Core Facility team for their support in BSL-3 procedures. We gratefully acknowledge the University of Maryland for the availability of the G-II machine for the study. This study was approved by the National Healthcare Group Domain Specific Review Board, reference number 2020/01113. Written informed consent was obtained from all study participants. M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Figure 1 

Viral load of SARS-CoV-2 in clinical samples

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients

Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals

Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients

Breathing, speaking, coughing or sneezing: What drives transmission of SARS-CoV-2?

SARS-CoV-2 transmission from people without COVID-19 symptoms

High SARS-CoV-2 attack rate following exposure at a choir practice

Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event

Evidence for lack of transmission by close contact and surface touch in a restaurant outbreak of COVID-19

A Rosetta Stone for understanding infectious drops and aerosols

What was the primary mode of smallpox transmission? Implications for biodefense

Aerosol Exposure of Cynomolgus Macaques to SARS-CoV-2 Results in More Severe Pathology than Existing Models

Establishment of an African green monkey model for COVID-19 and protection against re-infection

SARS-CoV-2 Aerosol Exhaled by Experimentally Infected Cynomolgus Monkeys

Development and performance evaluation of an exhaled-breath bioaerosol collector for influenza virus

Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19

Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols

Ten scientific reasons in support of airborne transmission of SARS-CoV-2

Indoor transmission of SARS-CoV-2

Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care

Lack of viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among PCR-positive air samples from hospital rooms and community isolation facilities

Culture-based virus isolation to evaluate potential infectivity of clinical specimens tested for COVID-19

SARS-CoV-2 variants reveal features critical for replication in primary human cells

Clinical and Virological Features of SARS-CoV-2 Variants of Concern: A Retrospective Cohort Study Comparing B. 1.1. 7 (Alpha), B. 1.315 (Beta), and B. 1.617. 2 (Delta)

SARS-CoV-2 variants of concern and variants under investigation in England

Just 2% of SARS-CoV-2− positive individuals carry 90% of the virus circulating in communities

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development

Antibody responses to SARS-CoV-2 in patients with COVID-19

Exhaled respiratory particles during singing and talking

Comparing aerosol concentrations and particle size distributions generated by singing, speaking and breathing

Epidemiologic evidence for airborne transmission of SARS-CoV-2 during church singing, Australia, 2020. Emerging infectious diseases 2021

High rate of SARS-CoV-2 transmission due to choir practice in France at the beginning of the COVID-19 pandemic

Transmission of SARS-CoV-2 in the Karaoke Room: An Outbreak of COVID-19 in Guangzhou, China, 2020

Aerosol transmission of SARS-CoV-2: inhalation as well as exhalation matters for COVID-19

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Rhinorrhea, fever, cough